Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab vs. docetaxel in patients with advanced NSCLC (POPLAR)
A Rittmeyer, A Spira, K Park, J Mazieres, J Vansteenkiste, M Ballinger, D Waterkamp, M Kowanetz, L Fehrenbacher · Pneumologie · 2016 · Heft 02
Bibliografische Angaben
Zusammenfassung
Background: In a Phase Ia clinical trial, atezolizumab (anti-PDL1) showed single-agent activity in NSCLC patients (pts) with the objective response rate (ORR) associated with PD-L1 expression on tumor-infiltrating immune cells (IC) and/or tumor cells (TC). Here we report results from the first randomized study comparing atezolizumab vs. docetaxel (doc) in unselected NSCLC pts with subgroup analyses by PD-L1-expression. Methods: 287 previously-treated NSCLC pts were stratified by PD-L1 IC status, histology (squamous vs. nonsquamous) and number of prior lines of therapy (1 or 2) and randomized (1:1) to 1200 mg IV…
